Published in Biologics on December 01, 2008
Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients? Mediators Inflamm (2014) 0.83
Bone mineral density and frequency of osteoporosis among Vietnamese women with early rheumatoid arthritis. Clin Rheumatol (2011) 0.80
Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics. BMC Musculoskelet Disord (2015) 0.79
Total glucosides of paeony prevents juxta-articular bone loss in experimental arthritis. BMC Complement Altern Med (2013) 0.77
A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis. J Bone Miner Metab (2012) 0.77
Skeletal complications of rheumatoid arthritis. Osteoporos Int (2017) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum (2002) 4.15
Generalised bone loss in patients with early rheumatoid arthritis. Lancet (1994) 3.93
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum (2000) 3.51
IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol (1999) 3.15
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest (2000) 3.15
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest (2003) 3.14
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res (1998) 2.72
Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol (1998) 2.68
Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum (2000) 2.61
Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res (1996) 2.47
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum (2006) 2.28
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med (2000) 2.20
Bone destruction in arthritis. Ann Rheum Dis (2002) 2.15
Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun (2000) 2.14
Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology (2000) 2.13
Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis (1995) 2.10
Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem (2001) 2.02
Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem (2001) 1.99
Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum (2000) 1.92
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum (2002) 1.84
Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest (1997) 1.81
Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis (1995) 1.73
Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum (1987) 1.73
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res (2003) 1.68
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.64
Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis (1993) 1.61
Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res (1999) 1.59
The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res (2001) 1.57
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res (1999) 1.47
High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum (2002) 1.44
Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis (2001) 1.41
Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol (2002) 1.38
Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood (1998) 1.36
Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis (2007) 1.36
Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun (1998) 1.33
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) (2005) 1.33
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis (2003) 1.30
Bone loss in unclassified polyarthritis and early rheumatoid arthritis is better detected by digital x ray radiogrammetry than dual x ray absorptiometry: relationship with disease activity and radiographic outcome. Ann Rheum Dis (2004) 1.28
Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum (2001) 1.26
Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther (2004) 1.25
Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology (1997) 1.25
Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res (2000) 1.20
The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum (1993) 1.19
Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today (2000) 1.14
Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.14
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther (2007) 1.13
Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone (2000) 1.12
Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflammation (1992) 1.10
Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol (2005) 1.08
The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum (2001) 1.05
Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem (1997) 1.03
Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol (2003) 1.03
Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res (1991) 1.02
RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum (2005) 1.01
Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheumatol (2003) 0.99
Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol (2001) 0.99
Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum (2003) 0.98
Effects of cytokines on alkaline phosphatase and osteocalcin production, calcification and calcium release by human osteoblastic cells. Br J Rheumatol (1994) 0.97
Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis (2005) 0.96
The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology (Oxford) (2006) 0.93
Longitudinal bone mineral density changes in early rheumatoid arthritis. Br J Rheumatol (1994) 0.93
Bone changes in early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2001) 0.93
Mineral density and histomorphometric assessment of bone changes in the proximal tibia early after induction of type II collagen-induced arthritis in growing and mature rats. J Bone Miner Metab (2001) 0.84
Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. J Rheumatol (1999) 0.84
An electron microscopic study of the synovial-bone junction in rheumatoid arthritis. Rheumatol Int (1984) 0.84
Rheumatoid arthritis and osteoporosis. Z Rheumatol (2000) 0.84
Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Curr Opin Rheumatol (2004) 0.83
Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients compared with osteoarthritis patients. Arthritis Rheum (2000) 0.83
Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis (2005) 0.82
Bone morphometric changes in adjuvant-induced polyarthritic osteopenia in rats: evidence for an early bone formation defect. J Bone Miner Res (1993) 0.82
The effect of natural and surgical menopause on the secretion of cytokines from human blood monocytes. Osteoporos Int (1993) 0.81
Hypercorticism blunts circadian variations of osteocalcin regardless of nutritional status. Bone (2002) 0.79
Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome. Osteoporos Int (2001) 0.78
Serum osteocalcin levels in premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci (2002) 0.78
How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy. Rev Rhum Engl Ed (1997) 0.76
Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol (2012) 2.70
IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 2.18
Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol (2014) 1.72
Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol (2002) 1.55
Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum (2003) 1.53
Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum (2012) 1.46
Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis (2011) 1.40
Rheumatoid arthritis after 9 years of human immunodeficiency virus infection: possible contribution of tritherapy. J Rheumatol (2002) 1.38
The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol (2007) 1.35
IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol (2008) 1.34
Peptidylpropyl isomerase B (PPIB): a suitable reference gene for mRNA quantification in peripheral whole blood. J Biotechnol (2004) 1.33
Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol (2008) 1.29
Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol (2009) 1.28
Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther (2004) 1.25
Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis. Arthritis Rheum (2012) 1.16
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther (2007) 1.13
Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS One (2010) 1.12
IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine (2007) 1.07
IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis (2010) 1.07
Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum (2004) 1.07
Isolation of regulatory T cells in the skin of a human hand-allograft, up to six years posttransplantation. Transplantation (2006) 1.06
Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis (2012) 1.02
Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT. Ann Rheum Dis (2010) 1.01
RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum (2005) 1.01
Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res Ther (2004) 0.99
Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis Rheum (2006) 0.95
Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol (2012) 0.95
Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. J Pathol (2004) 0.95
IFN-gamma, as secreted during an alloresponse, induces differentiation of monocytes into tolerogenic dendritic cells, resulting in FoxP3+ regulatory T cell promotion. J Immunol (2009) 0.94
mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. J Clin Immunol (2005) 0.93
IL-17 inhibits human Th1 differentiation through IL-12R beta 2 downregulation. Cytokine (2009) 0.92
Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine (2009) 0.92
Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis (2010) 0.91
FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Ann Rheum Dis (2009) 0.91
Immature muscle precursors are a source of interferon-β in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum (2012) 0.90
Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis. Joint Bone Spine (2010) 0.89
IL-17 in rheumatoid arthritis: a new target for treatment or just another cytokine? Joint Bone Spine (2004) 0.89
A comparative review of the different techniques to assess hand bone damage in rheumatoid arthritis. Joint Bone Spine (2010) 0.89
Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther (2010) 0.88
IL-17 and tumour necrosis factor α combination induces a HIF-1α-dependent invasive phenotype in synoviocytes. Ann Rheum Dis (2012) 0.88
Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol (2004) 0.88
Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope. Ann Rheum Dis (2006) 0.86
Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. PLoS One (2011) 0.85
Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells. Ann Rheum Dis (2012) 0.85
New regulatory rules for clinical trials in the United States and the European Union: key points and comparisons. Arthritis Rheum (2006) 0.85
Cytokine response in inflammatory myopathies. Curr Rheumatol Rep (2007) 0.84
Will steroidal aromatase inhibitors induce rheumatoid arthritis? Ann Rheum Dis (2007) 0.84
IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis (2007) 0.83
Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus. J Virol (2009) 0.83
Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance? Arthritis Res Ther (2009) 0.82
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Curr Med Res Opin (2010) 0.82
A rapid semi automated method for DNA extraction from dried-blood spots: application to the HLA-DR shared epitope analysis in rheumatoid arthritis. J Immunol Methods (2007) 0.81
Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol (2007) 0.81
Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep (2012) 0.81
Interleukin-17 and Th17 cells: from adult to juvenile arthritis--now it is serious! Arthritis Rheum (2011) 0.81
Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis. Arthritis Res Ther (2012) 0.81
Assessment of hand trabecular bone texture with high resolution direct digital radiograph in rheumatoid arthritis: a case control study. Joint Bone Spine (2011) 0.80
Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum (2008) 0.80
Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis. Muscle Nerve (2008) 0.80
Rheumatoid flat foot and deformity of the first ray. J Rheumatol (2002) 0.79
Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritis. Arthritis Res Ther (2003) 0.79
Prolidase deficiency: a rare aetiology of arthritis. Joint Bone Spine (2009) 0.78
Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2011) 0.78
Levels of soluble osteoclast-associated receptor (sOSCAR) in rheumatoid arthritis: link to disease severity and cardiovascular risk. Ann Rheum Dis (2014) 0.77
A critical role for immature muscle precursors in myositis. Nat Rev Rheumatol (2013) 0.76
Regulation of interleukin-18 binding protein production by blood and synovial cells from patients with rheumatoid arthritis. Arthritis Rheum (2004) 0.76
Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. Respir Med (2005) 0.76
Treatment with etanercept of autoimmune hepatitis associated with rheumatoid arthritis: an open label proof of concept study. Ann Rheum Dis (2012) 0.75
Immunoregulation in idiopathic inflammatory myopathies: from dendritic cells to immature regenerating muscle cells. J Rheumatol (2013) 0.75
Introduction: ‘Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?’. Arthritis Res Ther (2014) 0.75
Epstein Barr virus-induced hepatitis associated with methotrexate treatment. J Clin Gastroenterol (2008) 0.75
Lack of association of IL-10 promoter gene variants with type 1 diabetes in a French population. Hum Immunol (2006) 0.75